Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.BO)
INR 44.9
(-2.41%)
INR 44.9
(-2.41%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 25.49 Million INR | 110.13% |
| 2022 | 12.13 Million INR | -6.17% |
| 2021 | 12.93 Million INR | -70.23% |
| 2020 | 43.44 Million INR | 156.76% |
| 2019 | 16.92 Million INR | 42.09% |
| 2018 | 11.9 Million INR | 16.21% |
| 2017 | 10.24 Million INR | 516.24% |
| 2016 | 1.66 Million INR | 73.23% |
| 2015 | 960 Thousand INR | -42.33% |
| 2014 | 1.66 Million INR | -39.15% |
| 2013 | 2.73 Million INR | -15.14% |
| 2012 | 3.22 Million INR | 47.76% |
| 2011 | 2.18 Million INR | 246.06% |
| 2010 | 630.46 Thousand INR | 4691.88% |
| 2009 | 13.15 Thousand INR | -98.82% |
| 2008 | 1.11 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 50.73 Million INR | 0.0% |
| 2023 FY | 25.49 Million INR | 110.13% |
| 2023 Q4 | 25.49 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 12.13 Million INR | -6.17% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 12.13 Million INR | 0.0% |
| 2022 Q2 | 9.02 Million INR | 0.0% |
| 2021 FY | 12.93 Million INR | -70.23% |
| 2021 Q4 | 12.93 Million INR | 0.0% |
| 2021 Q2 | 10.98 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 11 Million INR | 0.0% |
| 2020 FY | 43.44 Million INR | 156.76% |
| 2020 Q4 | 43.44 Million INR | 0.0% |
| 2019 Q2 | 135.97 Million INR | 0.0% |
| 2019 FY | 16.92 Million INR | 42.09% |
| 2019 Q4 | 16.92 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 11.9 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 74.07 Million INR | 0.0% |
| 2018 FY | 11.9 Million INR | 16.21% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 1.02 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 10.24 Million INR | 0.0% |
| 2017 FY | 10.24 Million INR | 516.24% |
| 2016 Q4 | 1.66 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 1.66 Million INR | 73.23% |
| 2016 Q2 | 806.78 Thousand INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 960 Thousand INR | -42.33% |
| 2015 Q4 | 960 Thousand INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 1.88 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 2.62 Million INR | 40.81% |
| 2014 FY | 1.66 Million INR | -39.15% |
| 2014 Q4 | 1.66 Million INR | 0.0% |
| 2014 Q1 | 1.86 Million INR | -31.86% |
| 2013 FY | 2.73 Million INR | -15.14% |
| 2013 Q2 | 5.77 Million INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 2.73 Million INR | 0.0% |
| 2012 Q4 | 3.22 Million INR | 85.83% |
| 2012 Q3 | 1.73 Million INR | 0.0% |
| 2012 FY | 3.22 Million INR | 47.76% |
| 2011 Q4 | 2.18 Million INR | 0.0% |
| 2011 FY | 2.18 Million INR | 246.06% |
| 2010 FY | 630.46 Thousand INR | 4691.88% |
| 2009 FY | 13.15 Thousand INR | -98.82% |
| 2008 FY | 1.11 Million INR | 0.0% |
| 2008 Q4 | 1.11 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Bal Pharma Limited | 878.11 Million INR | 97.096% |
| Achyut Healthcare Limited | 568 Thousand INR | -4388.908% |
| Alkem Laboratories Limited | 26.61 Billion INR | 99.904% |
| Divi's Laboratories Limited | 31.84 Billion INR | 99.92% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 99.899% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 99.618% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | 73.973% |
| Mankind Pharma Limited | 15.53 Billion INR | 99.836% |
| Medicamen Biotech Limited | 593.75 Million INR | 95.706% |
| Medico Remedies Limited | 163.37 Million INR | 84.393% |
| Megasoft Limited | - INR | -Infinity% |
| Procter & Gamble Health Limited | 1.09 Billion INR | 97.663% |
| Piramal Pharma Limited | 21.75 Billion INR | 99.883% |
| Sequent Scientific Limited | 3.46 Billion INR | 99.264% |
| Sigachi Industries Limited | 707.2 Million INR | 96.395% |
| Ajanta Pharma Limited | 8.28 Billion INR | 99.692% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 99.974% |
| Brooks Laboratories Limited | 96.1 Million INR | 73.47% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 99.603% |
| Themis Medicare Limited | 705.74 Million INR | 96.387% |
| Unichem Laboratories Limited | 7.04 Billion INR | 99.638% |
| Hester Biosciences Limited | 755.81 Million INR | 96.627% |
| Venus Remedies Limited | 1.21 Billion INR | 97.905% |
| Indoco Remedies Limited | 3.53 Billion INR | 99.278% |
| Ind-Swift Limited | 640.91 Million INR | 96.022% |
| Aarti Drugs Limited | 4.85 Billion INR | 99.475% |
| Alpa Laboratories Limited | 136.65 Million INR | 81.342% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 98.881% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 99.96% |
| Granules India Limited | 13 Billion INR | 99.804% |
| Gufic Biosciences Limited | 2 Billion INR | 98.728% |
| Hikal Limited | 3.03 Billion INR | 99.161% |
| RPG Life Sciences Limited | 1.01 Billion INR | 97.476% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 98.897% |
| Windlas Biotech Limited | 621.89 Million INR | 95.9% |
| ZIM Laboratories Limited | 812.62 Million INR | 96.862% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | 75.619% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 99.4% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 99.802% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 99.974% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 98.23% |
| Ipca Laboratories Limited | 24.71 Billion INR | 99.897% |
| Lasa Supergenerics Limited | 190.43 Million INR | 86.611% |
| Laurus Labs Limited | 18.45 Billion INR | 99.862% |
| NATCO Pharma Limited | 7 Billion INR | 99.636% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 99.64% |
| Shilpa Medicare Limited | 3.44 Billion INR | 99.261% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 99.291% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 99.888% |
| Wanbury Limited | 360.23 Million INR | 92.922% |
| Wockhardt Limited | 6.4 Billion INR | 99.602% |
| Strides Pharma Science Limited | 11.26 Billion INR | 99.774% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 97.847% |
| Suven Life Sciences Limited | 7.08 Million INR | -259.873% |
| Amrutanjan Health Care Limited | 289.04 Million INR | 91.179% |
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 99.845% |
| Eris Lifesciences Limited | 1.89 Billion INR | 98.651% |
| Lupin Limited | 49.53 Billion INR | 99.949% |
| Sun Pharma Advanced Research Company Limited | - INR | -Infinity% |
| Syncom Formulations (India) Limited | 210.81 Million INR | 87.906% |
| Valiant Laboratories Limited | 100.15 Million INR | 74.542% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 99.926% |
| FDC Limited | 3.88 Billion INR | 99.344% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 99.493% |
| Novartis India Limited | 448.6 Million INR | 94.316% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | 82.999% |
| Neuland Laboratories Limited | 3.5 Billion INR | 99.272% |
| Morepen Laboratories Limited | 2.48 Billion INR | 98.974% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | 36.066% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 97.938% |